{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:29:05Z","timestamp":1787668145303,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejim.2021.09.008","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T15:04:14Z","timestamp":1633100654000},"page":"20-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Toxic nephropathy: Adverse renal effects caused by drugs"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-6031","authenticated-orcid":false,"given":"Robert J.","family":"Unwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2021.09.008_bib0001","first-page":"1","article-title":"Environmental chemistry and ecotoxicology of hazardous heavy metals: environmental persistence, toxicity, and bioaccumulation","volume":"2019","author":"Ali","year":"2019","journal-title":"J Chem-Ny"},{"key":"10.1016\/j.ejim.2021.09.008_bib0002","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bbrc.2018.06.029","article-title":"Molecular mechanism of the increased tissue uptake of trivalent inorganic arsenic in mice with type 1 diabetes mellitus","volume":"504","author":"Wei","year":"2018","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.ejim.2021.09.008_bib0003","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/0886022X.2015.1013419","article-title":"Arsenic-mediated nephrotoxicity","volume":"37","author":"Robles-Osorio","year":"2015","journal-title":"Renal Failure"},{"key":"10.1016\/j.ejim.2021.09.008_bib0004","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1369\/0022155416641028","article-title":"A systematic characterization of Aquaporin-9 expression in human normal and pathological tissues","volume":"64","author":"Lindskog","year":"2016","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.ejim.2021.09.008_bib0005","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.3892\/mmr.2017.6389","article-title":"Kidney and heavy metals - the role of environmental exposure","volume":"15","author":"Lentini","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ejim.2021.09.008_bib0006","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10534-010-9328-y","article-title":"Heavy metal poisoning: the effects of cadmium on the kidney","volume":"23","author":"Johri","year":"2010","journal-title":"Biometals"},{"key":"10.1016\/j.ejim.2021.09.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2014.04.058","article-title":"Acute kidney injury associated with high nephrotoxic medication exposure leads to chronic kidney disease after 6 months","author":"Menon","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.ejim.2021.09.008_bib0008","first-page":"1","article-title":"Drug toxicity in the proximal tubule: new models, methods and mechanisms","author":"Hall","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ejim.2021.09.008_bib0009","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12086","article-title":"Renal drug metabolism in humans: the potential for drug\u2013endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)","volume":"76","author":"Knights","year":"2013","journal-title":"Brit J Clin Pharmaco"},{"key":"10.1016\/j.ejim.2021.09.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.118.082958","article-title":"Emerging kidney models to investigate metabolism, transport and toxicity of drugs and xenobiotics","volume":"46","author":"Bajaj","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejim.2021.09.008_bib0011","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ki.1989.70","article-title":"Snake-bite-induced acute renal failure in India","volume":"35","author":"Chugh","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2021.09.008_bib0012","first-page":"572","article-title":"Caring for glucose-6-phosphate dehydrogenase (G6PD)\u2013deficient patients: implications for pharmacy","volume":"40","author":"Bubp","year":"2015","journal-title":"P&T"},{"key":"10.1016\/j.ejim.2021.09.008_bib0013","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/0886022X.2019.1628780","article-title":"Acute toxic kidney injury","volume":"41","author":"Petejova","year":"2019","journal-title":"Renal Failure"},{"key":"10.1016\/j.ejim.2021.09.008_bib0014","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cpdd.879","article-title":"A review on drug-induced nephrotoxicity: pathophysiological mechanisms, drug classes, clinical management, and recent advances in mathematical modeling and simulation approaches","volume":"9","author":"Mody","year":"2020","journal-title":"Clin Pharm Drug Dev"},{"key":"10.1016\/j.ejim.2021.09.008_bib0015","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2215\/CJN.11571017","article-title":"Nephrotoxicity and Chinese herbal medicine","volume":"13","author":"Yang","year":"2018","journal-title":"Clin J Am Soc Nephro"},{"key":"10.1016\/j.ejim.2021.09.008_bib0016","first-page":"419","volume":"13","author":"Cook","year":"2014"},{"key":"10.1016\/j.ejim.2021.09.008_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1088\/1758-5090\/8\/1\/015021","article-title":"Pharmacokinetic profile that reduces nephrotoxicity of gentamicin in a perfused kidney-on-a-chip","volume":"8","author":"Kim","year":"2016","journal-title":"Biofabrication"},{"key":"10.1016\/j.ejim.2021.09.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1021\/acs.nanolett.1c01840","article-title":"Nephrotoxicity assessment with human kidney tubuloids using spherical nucleic acid-based mRNA nanoflares","author":"Wiraja","year":"2021","journal-title":"Nano Lett"},{"key":"10.1016\/j.ejim.2021.09.008_bib0019","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.00150118","article-title":"Pharmacology behind common drug nephrotoxicities","author":"Perazella","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2021.09.008_bib0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2215\/CJN.13841217","article-title":"Utility of electronic medical record alerts to prevent drug nephrotoxicity","volume":"14","author":"Martin","year":"2019","journal-title":"Clin J Am Soc Nephro"},{"key":"10.1016\/j.ejim.2021.09.008_bib0021","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2215\/CJN.15020920","article-title":"Digital applications targeting medication safety in ambulatory high-risk CKD patients: randomized controlled clinical trial","volume":"16","author":"Ong","year":"2021","journal-title":"Clin J Am Soc Nephro"},{"key":"10.1016\/j.ejim.2021.09.008_bib0022","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2021010063","article-title":"Self-reported medication use and urinary drug metabolites in the German chronic kidney disease (GCKD) study","author":"Kotsis","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2021.09.008_bib0023","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nbt.1625","article-title":"Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium","volume":"28","author":"Dieterle","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ejim.2021.09.008_bib0024","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12882-017-0536-3","article-title":"The 6R's of drug induced nephrotoxicity","volume":"18","author":"Awdishu","year":"2017","journal-title":"Bmc Nephrol"},{"key":"10.1016\/j.ejim.2021.09.008_bib0025","doi-asserted-by":"crossref","first-page":"s82","DOI":"10.1590\/1806-9282.66.s1.82","article-title":"Drug-induced nephrotoxicity","volume":"66","author":"Sales","year":"2020","journal-title":"Revista Da Assoc M\u00e9dica Brasileira"},{"key":"10.1016\/j.ejim.2021.09.008_bib0026","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00546706","article-title":"Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?","volume":"26","author":"Ramsay","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2021.09.008_bib0027","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1159\/000510433","article-title":"Genotype-guided hydralazine therapy","volume":"51","author":"Collins","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ejim.2021.09.008_bib0028","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.kint.2021.03.029","article-title":"Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine","volume":"100","author":"Santoriello","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2021.09.008_bib0029","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1053\/j.ajkd.2009.07.012","article-title":"Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis","volume":"54","author":"Hall","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2021.09.008_bib0030","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","article-title":"Tenofovir-associated renal and bone toxicity","volume":"10","author":"Woodward","year":"2009","journal-title":"Hiv Med"},{"key":"10.1016\/j.ejim.2021.09.008_bib0031","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/0972-3919.119541","article-title":"Bone scintigraphic patterns in patients of tumor induced osteomalacia","volume":"28","author":"Sood","year":"2013","journal-title":"Indian J Nucl Medicine"},{"key":"10.1016\/j.ejim.2021.09.008_bib0032","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/qjmed\/hct258","article-title":"Drug-induced renal Fanconi syndrome","volume":"107","author":"Hall","year":"2014","journal-title":"Qjm Int J Medicine"},{"key":"10.1016\/j.ejim.2021.09.008_bib0033","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1002\/jcph.735","article-title":"Renal transporter-mediated drug-drug interactions: are they clinically relevant?","volume":"56","author":"Lepist","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2021.09.008_bib0034","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1248\/bpb.33.1867","article-title":"Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity","volume":"33","author":"Katsuda","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ejim.2021.09.008_bib0035","first-page":"kfaa181","article-title":"Urinary miRNA biomarkers of drug-induced kidney injury and their site specificity within the nephron","volume":"180","author":"Chorley","year":"2020","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.ejim.2021.09.008_bib0036","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir Res"},{"key":"10.1016\/j.ejim.2021.09.008_bib0037","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ki.1978.6","article-title":"Epidemiological study in Switzerland","volume":"13","author":"Dubach","year":"1978","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2021.09.008_bib0038","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/ki.1978.11","article-title":"Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia","volume":"13","author":"Nanra","year":"1978","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2021.09.008_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IMCRJ.S71471","article-title":"Paracetamol and analgesic nephropathy: are you kidneying me?","volume":"Volume 8","author":"Waddington","year":"2014","journal-title":"Int Medical Case Reports J"},{"key":"10.1016\/j.ejim.2021.09.008_bib0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00002018-199920010-00003","article-title":"Analgesic nephropathy","volume":"20","author":"Elseviers","year":"1999","journal-title":"Drug Safety"},{"key":"10.1016\/j.ejim.2021.09.008_bib0041","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ki.1995.416","article-title":"High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure","volume":"48","author":"Elseviers","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2021.09.008_bib0042","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.4.5728.131","article-title":"Phenacetin nephropathy, with particular reference to the effect of surgery","volume":"4","author":"Koutsaimanis","year":"1970","journal-title":"Brit Med J"},{"key":"10.1016\/j.ejim.2021.09.008_bib0043","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0049-3848(03)00416-X","article-title":"Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro","volume":"110","author":"Kankuri","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2021.09.008_bib0044","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1093\/ndt\/gfl390","article-title":"Obituary to analgesic nephropathy\u2014an autopsy study","volume":"21","author":"Mihatsch","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.ejim.2021.09.008_bib0045","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/ndt\/gfn643","article-title":"Non-phenacetin analgesics and analgesic nephropathy clinical assessment of high users from a case-control study","volume":"24","author":"Michielsen","year":"2008","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.ejim.2021.09.008_bib0046","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/jgs.16961","article-title":"Association of non-steroidal anti-inflammatory drugs with kidney health in ambulatory older adults","volume":"69","author":"Amatruda","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ejim.2021.09.008_bib0047","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.34067\/KID.0001742021","article-title":"The challenges of acute interstitial nephritis: time to standardize","volume":"2","author":"Moledina","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.ejim.2021.09.008_bib0048","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2215\/CJN.01390118","article-title":"Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis","volume":"13","author":"Fernandez-Juarez","year":"2018","journal-title":"Clin J Am Soc Nephro"},{"key":"10.1016\/j.ejim.2021.09.008_bib0049","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2021.09.008_bib0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521003083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521003083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:36:37Z","timestamp":1760607397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521003083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":50,"alternative-id":["S0953620521003083"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.09.008","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxic nephropathy: Adverse renal effects caused by drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}